Replies to post #329685 on Avid Bioservices Inc (CDMO)

[Threes]

The new BOD took control Jan 2018, so it's been not quite 13 months.
The first 3 to six months was about cutting non CDMO expenses. Then there has been the shut down and makeover of the usable space and updating methods. A Lot of compliance stuff. I would think the last six months the new team can claim responsibility. They expanded services we offer in the consultation and compliance assistance for early clinical and early phase trials. Remember there are barriers for the R&D customer that will make moving from AVID a hardship. So if we get a good one we will have them for the ride straight through to NDA and market supply. We are in the early stages of a great business model in a growing market. That does not make it easy , but, IMO we are on the way.
In my business I make chase a deal for months, some 18 months. I expect we are still in the early stages scaling up the pipeline on the sales side. we should definitely get solid guidance on the next CC. Would love a PR of sales , but, never though they would talk much between CC's.

Results and some sales should be visible in the next Q and eclipsed going forward from there.

[north40000]

"This thing trades all over the place....high volume some days, and low volume others and none of it makes a lot of sense..."

That has been true, of late, of all biotechs we own or have on a watch list. CDMO is not alone except it may have fewer PRs and rumors than others. Its Conference slides are nice, but still filled with a lot of generalities about what has been done and will be done.

Yesterday, for example, AMRN traded ~28-29 million shares. Average 10-day trading volume is 7 million. Who was trading that volume and why? Scrips for Vascepa(mostly off-label scrips, IMO) were posted early Friday morning. Message Board discussion was fueled by rumors of various sorts, including mostly rumors of buy-out by NVS or PFE. There was an on-going lipid conference in Portland, Oregon about which I know very little other than Amarin-connected folks made a presentation yesterday AH and AMRN had a booth with handouts. There is a Leerink conference next week. Earnings CC is due. A sNDA will be filed sometime by 3/31/2019 to format results and expanded label discussions/negotiations re Reduce-It clinical trial with FDA. Those results were known last year [11/10/2018 AHA and 9/24/2018 PR]. At least we have reason to believe AMRN will not be a repeat of PPHM and its Bavi Phase-3 trial.

https://investor.amarincorp.com/static-files/ace3d85c-408a-4322-b52c-9e2506f5558b

CDMO will have its better days soon. Our shares of CDMO in IRA are all profitable; the non-profitable shares[far more] are parked elsewhere in other accounts.